Otrivine Adult Menthol (Xylometazoline Hydrochloride)

Xylometazoline hydrochloride, the active ingredient in Otrivine Adult Menthol, is a nasal decongestant presented as a nasal spray for topical intranasal use. It relieves nasal blockage caused by colds, allergic rhinitis and sinusitis in adults. GNH USA supplies Otrivine Adult Menthol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Otrivine Adult Menthol, a topical nasal decongestant, is indicated for conditions that cause nasal airway obstruction. - Nasal congestion due to common cold: provides rapid reduction of swelling and improves airflow. - Allergic rhinitis: alleviates obstruction caused by allergic inflammation. - Acute sinusitis: helps clear the nasal passages to facilitate drainage and breathing.

Adverse reactions may occur with intranasal use of Otrivine Adult Menthol.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing or mild headache. - Altered taste or mild throat discomfort.

Serious or Rare Side Effects: - Rebound nasal congestion (rhinitis medicamentosa) after prolonged use. - Severe hypertension or arrhythmia. - Nasal ulceration or epistaxis. - Anaphylactic reaction or severe hypersensitivity.

Before using Otrivine Adult Menthol, consider the following precautions. - Duration of use: limit to 3‑5 consecutive days to avoid rebound congestion. - Hypertension: avoid or use under medical supervision if you have high blood pressure. - Pregnancy and lactation: consult a healthcare professional before use. - Age restriction: not recommended for children under 12 years of age. - Concomitant sympathomimetics: avoid using with other nasal decongestants to prevent excessive vasoconstriction. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Xylometazoline may interact with other medicines that affect the cardiovascular or sympathetic systems.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other topical nasal decongestants (e.g., phenylephrine): additive vasoconstriction may cause severe hypertension. - Systemic sympathomimetics (e.g., pseudoephedrine): may amplify cardiovascular effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia induced by xylometazoline. - Antihypertensive agents: possible reduction in blood‑pressure‑lowering effect. - Tricyclic antidepressants: monitor for increased cardiovascular stimulation.